Vobatricine






Names

    • Vobatricine

Attributes

  • Canonical SMILES

    C/C=C/1\CN([C@H]2CC3=C([C@@H](C[C@@H]1[C@@H]2C(=O)OC)C4=CC5=C(C=C4)NC6=C([C@H]\7C[C@H]8C56CCN8C/C7=C\C)C=O)NC9=CC=CC=C39)C

  • InChI

    InChI=1S/C40H44N4O3/c1-5-22-19-43(3)34-17-29-25-9-7-8-10-32(25)41-37(29)28(16-27(22)36(34)39(46)47-4)24-11-12-33-31(15-24)40-13-14-44-20-23(6-2)26(18-35(40)44)30(21-45)38(40)42-33/h5-12,15,21,26-28,34-36,41-42H,13-14,16-20H2,1-4H3/b22-5+,23-6+/t26-,27-,28-,34-,35-,36-,40?/m0/s1

  • Molecule Class: Alkaloids
  • TPSA: 77.67
  • #RotBonds: 3
  • MW: 628.8170000000002
  • HBD: 2
  • HBA: 6
  • logP: 6.082100000000006
  • Chemical Formula: C40H44N4O3


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. corymbosa Malaysia, China 1679252 GK604

External Databases


References

  • Vobatensines A-F, Cytotoxic Iboga-Vobasine Bisindoles from Tabernaemontana corymbosa. J Nat Prod, 2016 (PMID 26918761).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Growth inhibitory

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -5.52
    Human Oral Bioavailability 20% Non-Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -2.77
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability 340.31
    Distribution Blood-Brain Barrier (Central Nervous System) -2.19
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 1.21
    Plasma Protein Binding 78.27
    Steady State Volume of Distribution 4.69
    Metabolism Breast Cancer Resistance Protein Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Non-Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Non-Substrate
    CYP 3A4 Inhibitor Non-Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 12.73
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Toxic
    Avian Safe
    Bee Toxic
    Bioconcentration Factor -3.47
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -0.76
    Liver Injury II Toxic
    hERG Blockers Toxic
    Daphnia Maga 7.12
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Toxic
    T. Pyriformis -619249.43
    Rat (Acute) 3.14
    Rat (Chronic Oral) 1.97
    Fathead Minnow 787.61
    Respiratory Disease Toxic
    Skin Sensitisation Toxic
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 66414.19
    Hydration Free Energy -2.92
    Log(D) at pH=7.4 4.57
    Log(P) 5.32
    Log S -4.97
    Log(Vapor Pressure) -2144.52
    Melting Point 224.64
    pKa Acid 5.8
    pKa Basic 7.08